Health Economics & Outcomes Research Fellowships 2018
Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, dermatology, organ transplantation, oncology and hematology and other therapeutic areas.

Novartis, derived from the Latin novae artes, meaning “new skills,” is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HE&OR) and Global Oncology Market Access and Policy (GMAP) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.

Purpose
The Health Economics & Outcomes Research Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. There are 1-year and 2-year programs that are structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.

Overview
Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research Fellowship positions and up to two 1-year Post-Doctoral Fellowships in 2018.

For the 2-year Fellowship positions, the objective of the first year is to educate the Fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the Fellow will participate in ongoing outcomes research projects at the first-year Fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey. While at Novartis, “field-based” training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and learn how a pharmaceutical manufacturer uses clinical, economic and humanistic data to support the development and commercialization of its products. The Fellowship positions differ by first-year site, requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

For the 2-year Fellowship positions, the objective of the first year is to educate the Fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the Fellow will participate in ongoing outcomes research projects at the first-year Fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey. While at Novartis, “field-based” training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and learn how a pharmaceutical manufacturer uses clinical, economic and humanistic data to support the development and commercialization of its products. The Fellowship positions differ by first-year site, requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

Novartis will also offer up to two 1-year, full-time, Post-Doctoral Fellowship positions at Novartis Pharmaceuticals Corporation and/or Novartis Oncology. This Fellowship is open to candidates with a PhD (preferred) or Master’s in a health economics, outcomes research, or market access-related fields of study, such as Health Economics, Health Services Research, or Epidemiology. Fellows will be based at Novartis in East Hanover, New Jersey. Post-Doctoral Fellows will have training and hands-on experience in a broad range of health economics and outcomes research activities.

First Year Fellowship Sites for 2-Year Programs:
• Baylor Scott & White Health, Temple, TX/ The University of Texas at Austin, Austin, TX
• Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD
• Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Contact
Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:
For PharmD candidates:
Joseph Goble, PharmD
Health Economics & Outcomes Research Fellow
(862) 778-2740
joseph.goble@novartis.com

For PhD/MPH/MS candidates:
Rahul Garg, PhD
Health Economics & Outcomes Research Fellow
(862) 778-6134
rahul-1.garg@novartis.com

For PhD/MPH/MS candidates:
Rahul Garg, PhD
Health Economics & Outcomes Research Fellow
(862) 778-6134
rahul-1.garg@novartis.com
Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin

**Fellowship Sites & Preceptors**

Baylor Scott & White Health  
Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Specialty Clinical Pharmacy Services, Temple, TX  
James Wilson, PhD, PharmD, FASHP, Associate Professor, Austin, TX  

The University of Texas at Austin College of Pharmacy  
Joseph Goble, PharmD  
Pharmacy Services, Temple, TX  

Novartis Pharmaceuticals Corporation  
Kristen Johnson, PhD, MPH, Director, Health Economics & Outcomes Research, East Hanover, NJ

---

Baylor Scott & White Health/The University of Texas

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 316,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 3,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the components of the institution. Included are clinical services in a variety of environments for all health plans, as well as sponsorship of pharmaceutical research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in downtown Austin, and the Fellows are offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College has a Center for Pharmaceutical Economics Studies that currently has eight researchers on staff and conducts a variety of outcomes research studies each year.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

---

**Eligibility**

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or another related area. Experience in, or of a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

**Information**

For questions or additional information, please contact:

Joseph Goble, PharmD  
Health Economics & Outcomes Research Fellow  
Phone: (862) 778-2740  
Email: joseph.goble@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.

---

**Second-Year Fellow:**

**Joseph A. Goble, PharmD**

Joe Goble is the second-year Health Economics & Outcomes Research (HE&OR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH) and the University of Texas at Austin.

Joe received his Doctor of Pharmacy degree from the University of Maryland, Baltimore. Prior to the Fellowship, he gained a variety of valuable experiences in research, managed care, and pharmaceutical consulting. In these experiences, Joe performed various functions across formulary management, drug contracting, and value proposition, enhancing his understanding of the US healthcare landscape.

In the first year of the Fellowship, Joe conducted various outcomes research projects, supported the P&T committee and provided financial analysis to make operational decisions. He was actively involved in evaluation of pharmacy benefit performance and solutions to enhance associated quality metrics for health outcomes within Baylor Quality Alliance, the system's accountable care organization. He also worked on a project evaluating increased bleeding risk associated with oral factor Xa drug-dug interactions.

In his second year at Novartis, he supports the US HE&OR Neuroscience therapeutic area and Innovations & Partnerships team by managing research studies and supporting product launches. In addition, Joe is involved in protocol review, strategic planning, and outcomes-based contracting. Joe is also working toward earning a Master’s degree in Pharmaceutical Sciences from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.

---

**First-Year Fellow:**

**Esther Jihee Yi, PharmD**

Esther Jihee Yi is the first-year Health Economics & Outcomes Research (HE&OR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH) and the University of Texas at Austin.

Esther received her Doctor of Pharmacy degree from the University of California, San Francisco (UCSF) and brings to the program her valuable experiences from industry, managed care, health services and policy research, and regulatory sciences. At Genentech, she supported the Managed Care and Medical Communications department to provide evidence-based literature and guideline insights in support of new indications for the Lung Cancer Franchise. During her internship, she also evaluated the WHO Essential Medicines List decision making process and presented her research at the 2015 European DMA Conference in Paris, France. Her regulatory experiences include planning the FDA Naloxone App Competition as well as collaborating with UCSF-Stanford CERSI to evaluate the role of patient preferences in medical device approval. At UCSF, Esther conducted a study evaluating the impact of a pro-generic policy in Argentina on pricing and utilization, which she presented at the 2017 ISPOR Latin America Conference in Sao Paulo, Brazil. Other relevant experiences include her role as student body president for the UCSF School of Pharmacy and student representative on the UC Student Health Insurance Plan Formulary Committee.

During the first year, Esther conducts outcomes research, supports the P&T committee, and provides financial analyses for the operational decisions of BSWH. Her current projects include evaluating primary nonadherence to antibiotic medications using BSWH pharmacy point-of-sale data and assessing the impact of a Value Based Insurance Design program using a Chronic and Preventative Medication List on patient outcomes. In addition, Esther is also working towards earning a Master’s degree in Pharmaceutical Sciences from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.
Novartis Pharmaceuticals Corporation/
University of Maryland School of Pharmacy

Fellowship Sites & Preceptors
University of Maryland School of Pharmacy
Linda Simone-Wastila, BSPharm, MSPH, PhD, Professor, Department of Pharmaceutical Health Services Research, Baltimore, MD
Novartis Pharmaceuticals Corporation
Kristen Johnson, PhD, MPH, Director, Health Economics & Outcomes Research, East Hanover, NJ

The University of Maryland School of Pharmacy

The University of Maryland School of Pharmacy, founded in 1841, is the fourth oldest school of pharmacy in the nation. The School of Pharmacy is one of seven professional schools and a graduate school located at the University of Maryland, Baltimore, a thriving center for health services practice and research. Through its education, research and service programs, the School of Pharmacy strives to improve the health and well-being of society by aiding in the discovery, development and optimal use of medicines. One of three departments within the School, the Department of Pharmaceutical Health Services Research (PHSR) aims to improve the health of diverse populations through pharmaceutical health services research, education, service and community outreach.

PHSR scholarship spans the disciplines of behavioral sciences, pharmacoeconomics, pharmacoepidemiology and policy. Fifteen faculty members conduct research sponsored by federal and state governmental agencies, foundations and the pharmaceutical industry. Work clusters around issues inherent in the Department’s Centers: The Peter Lamy Center on Drug Therapy and Aging, the Peter Lamy Center on Drugs and Public Policy. Pharmaceutical Services and Research, a third Departmental center, provides computer programming, data management and analytic support to faculty, students and staff.

The Department houses numerous comprehensive databases, including the Chronic Condition Warehouse (CCW) 9% sample of Medicare beneficiaries linked to Part D data, the Medicare Current Beneficiary Survey, Medicaid and MAX data, and other proprietary and public data sets.

This two-year Fellowship focuses on the development of research skills relevant to health policy, with a particular focus on pharmacoeconomic policy. Fellows will spend the first year at the University of Maryland Baltimore honing research and policy skills and the second year at Novartis, where they will apply training and interests in an industry environment. Broad domains of interest include research focusing on medication management and outcomes in geriatric patients suffering multiple chronic illnesses, Medicare policy, long-term care policy, mental health policy, patient-centered outcomes research and comparative effectiveness research. The successful applicant will work closely with a mentoring team to identify relevant research areas and training opportunities. The unique combination of rigorous academic training with industry experience in the second year will provide the fellow considerable experience to conduct policy-relevant health services and outcomes research.

Eligibility

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information

For questions or additional information, please contact:
Michelle Choi, PharmD
Health Economics & Outcomes Research Fellow
Phone: (862) 778-2737
Email: michelle.choi@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution:

Michelle received her Doctor of Pharmacy degree from the University of Washington (UW) School of Pharmacy. She gained valuable experiences within a clinical trial site, the FDA, and various managed care organizations. At Premera Blue Cross, she conducted a cost-utility analysis on the addition of ixabradine to Premera’s value-based formulary. During an internship with Blue Cross Blue Shield Association, she worked with the Integrated Care Management team on projecting plan impact of implementing a preferred drug program for fgrastrim-snd to the Federal Employee Program formulary.

During her first year at the University of Maryland (UMB), Michelle took courses in research methodology and biostatistics. With guidance from the UMB Pharmaceutical Health Sciences Research faculty, she was involved in various outcomes and policy-focused studies, which included analyzing the change in patterns of controlled prescription drug utilization with the adoption of the Prescription Drug Monitoring Program. She led a study assessing the impact of expanded maximum number of patients per buprenorphine prescriber on the prescribing patterns of opioids and buprenorphine in Maryland and the surrounding states.

In her second year at Novartis, Michelle assists the US HE&OR cardiovascular business unit. She is currently supporting projects involving multicenter chart reviews, patient-reported outcomes, retrospective claims analyses, and strategic planning.

Second-Year Fellow:
Michelle E. Choi, PharmD

Natalie Park is the first-year Health Economics & Outcomes Research (HE&OR) Fellow with the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Natalie received her Doctor of Pharmacy degree from the Ohio State University College of Pharmacy where she completed additional coursework in biostatistics, SAS, epidemiology, and US healthcare policy and delivery system. During pharmacy school Natalie had a number of valuable experiences, which encouraged her to pursue a fellowship in HEOR. As an intern in the US HEOR team at Celgene, Natalie led electronic medical record analyses to generate evidence to demonstrate the value of Abraxane® in metastatic pancreatic cancer population. At DataMed Solutions LLC, she analyzed and educated internal and external stakeholders regarding available value frameworks (i.e., ASCO, ICER, Drug Abacus). At Precision for Value, Natalie was part of the payer strategies team where she generated value propositions to ensure a successful new drug launch, built an unsolicited customer-facing tools, and developed effective communication strategies to educate payers and providers on disease burden and unmet needs. Additionally, she served on the Ohio State student health insurance advisory committee analyzing healthcare resource utilization and cost patterns to guide medical and pharmacy benefit designs and implement appropriate utilization management strategies.

During her first year at the University of Maryland Baltimore Natalie will take PhD-level courses in research methodology and statistics. Currently she is involved with multiple research projects studying outcomes related to health policies in antipsychotics and medical marijuana as well as opioid utilization in COPD population.

First-Year Fellow:
Natalie Park, PharmD

Michelle Choi is the second-year Health Economics & Outcomes Research (HE&OR) Fellow with the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Michelle received her Doctor of Pharmacy degree from the University of Washington (UW) School of Pharmacy. She gained valuable experiences within a clinical trial site, the FDA, and various managed care organizations. At Premera Blue Cross, she conducted a cost-utility analysis on the addition of ixabradine to Premera’s value-based formulary. During an internship with Blue Cross Blue Shield Association, she worked with the Integrated Care Management team on projecting plan impact of implementing a preferred drug program for fgrastrim-snd to the Federal Employee Program formulary.

During her first year at the University of Maryland (UMB), Michelle took courses in research methodology and biostatistics. With guidance from the UMB Pharmaceutical Health Sciences Research faculty, she was involved in various outcomes and policy-focused studies, which included analyzing the change in patterns of controlled prescription drug utilization with the adoption of the Prescription Drug Monitoring Program. She led a study assessing the impact of expanded maximum number of patients per buprenorphine prescriber on the prescribing patterns of opioids and buprenorphine in Maryland and the surrounding states.

In her second year at Novartis, Michelle assists the US HE&OR cardiovascular business unit. She is currently supporting projects involving multicenter chart reviews, patient-reported outcomes, retrospective claims analyses, and strategic planning.

Second-Year Fellow:
Michelle E. Choi, PharmD

Michelle Choi is the second-year Health Economics & Outcomes Research (HE&OR) Fellow with the University of Maryland School of Pharmacy and Novartis Pharmaceuticals Corporation.

Michelle received her Doctor of Pharmacy degree from the University of Washington (UW) School of Pharmacy. She gained valuable experiences within a clinical trial site, the FDA, and various managed care organizations. At Premera Blue Cross, she conducted a cost-utility analysis on the addition of ixabradine to Premera’s value-based formulary. During an internship with Blue Cross Blue Shield Association, she worked with the Integrated Care Management team on projecting plan impact of implementing a preferred drug program for fgrastrim-snd to the Federal Employee Program formulary.

During her first year at the University of Maryland (UMB), Michelle took courses in research methodology and biostatistics. With guidance from the UMB Pharmaceutical Health Sciences Research faculty, she was involved in various outcomes and policy-focused studies, which included analyzing the change in patterns of controlled prescription drug utilization with the adoption of the Prescription Drug Monitoring Program. She led a study assessing the impact of expanded maximum number of patients per buprenorphine prescriber on the prescribing patterns of opioids and buprenorphine in Maryland and the surrounding states.

In her second year at Novartis, Michelle assists the US HE&OR cardiovascular business unit. She is currently supporting projects involving multicenter chart reviews, patient-reported outcomes, retrospective claims analyses, and strategic planning.

Second-Year Fellow:
Michelle E. Choi, PharmD
Health Economics & Outcomes Research Fellowships

Novartis Pharmaceuticals Corporation/Thomas Jefferson University, Jefferson College of Population Health

Fellowship Sites & Preceptors

Thomas Jefferson University
Vittorio Mao, PharmD, MS, MSPH, Professor Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

Novartis Pharmaceuticals Corporation
Kristen Johnson, PhD, MPH, Director, Health Economics & Outcomes Research, East Hanover, NJ

College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson’s Department of Health Policy and specializes in all key areas of population health, public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research fellowship programs in the country. To date, more than 40 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University’s Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, the Fellow will have the opportunity to present at and attend research meetings, journal clubs, Population Health Forums and sponsored educational programs. During this time, the Fellow will work with JCPH faculty to work on various projects. Some of her projects focus on cost-benefit analysis (CBA), claims analyses, chart reviews, patient reported outcomes and systematic review research studies. The following summer, she is continuing coursework towards earning a Master Degree in Applied Health Economics and Outcomes Research from JCPH.

During her first year at Jefferson College of Population Health, Lauren gained experience applying the principles of outcomes research, economic modeling, quality measures, large retrospective cohort analyses and value based framework. Her research resulted in multiple poster presentations at the 2017 Annual Meeting of the International Society for Pharmaceutical economics and Outcomes Research (ISPOR) and the Academy of Managed Care Pharmacy (AMCP) conferences.

Prior to the fellowship, Lauren participated in multiple research projects including health disparities, clinical outcomes and systematic review research studies. Her research projects focused on factors that contribute to poor health outcomes and increase cost in heart failure, ADHD and Alzheimer’s patients. She also got exposure to HEOR projects at Daiichi Sankyo and Cardinal Health specialty pharmacy during her fourth year rotations. She was an active member of Student National Pharmaceutical Association (SNPhA), Academy of Managed Care Pharmacy (AMCP) and Phi Delta Chi (PDC).

Eligibility

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and a Master of Science degree program in public health, population health, health policy or applied health economics and outcomes research.

Information

For questions or additional information, please contact:
Laurence Djatche, PharmD
Health Economics & Outcomes Research Fellow
Phone: (609) 778-2547
Email: laurence.djatche@novartis.com

All questions regarding potential visa sponsorship should be directed to the collaborating institution.
Fellowship Sites & Preceptors
Novartis Pharmaceuticals Corporation
Kristen Johnson, PhD, MPH, Director, Health Economics & Outcomes Research, East Hanover, NJ

Novartis Oncology
Helen Lau, MS, Director, Global Oncology Market Access and Policy (GMAP), East Hanover, NJ

Summary:
The US Health Economics and Outcomes Research (US HEOR) and Global Oncology Market Access and Policy (GMAP) teams are pleased to offer one-year, full-time Fellowships within each department with opportunities to work with health economics and outcomes research and/or, market access, pricing, and policy professionals to support the Novartis business areas.

Fellows will have opportunities to participate in research studies and projects to gain experience in how a pharmaceutical company uses clinical, economic, and humanistic data to support the development and commercialization of products. Specifically, the Fellow will have opportunities to gain experience across a product life-cycle including the early development stages, pre-launch and post-product launch stages, in the neuroscience, respiratory, dermatology, cardiovascular, and transplant franchises within Novartis Pharmaceuticals or the Novartis Oncology business unit.

Specifically, the Fellows would provide opportunities to work on the following:

• Business application of HEOR research
• Build on research skills including study methodology through the execution of HEOR research studies
• Research activities may include literature reviews within a specified disease or therapeutic area, development of economic models, medical chart review studies, patient surveys, database analyses, burden of illness studies, and PRO development
• Research publications and presentations
• Development of global market access and pricing strategy (Global Oncology specific)
• Project management experience

Eligibility
Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, public administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

Information
For questions or additional information, please contact:
Rahul Garg, PhD
Health Economics & Outcomes Research Fellow
Phone: (862) 778-8134
Email: rahul-1.garg@novartis.com

This position requires appropriate authorization for US employment for the entire Fellowship period.

The Global Oncology Market Access and Policy (GMAP) Fellowship is not currently recruiting for 2018.

Post-Doctoral Fellow:
Batul Electricwala, PhD, BPharm

Batul Electricwala is a post-doctoral Health Economics & Outcomes Research Fellow with Novartis Pharmaceuticals Corporation.

Batul received her Bachelor of Pharmacy (BPharm) from Institute of Chemical Technology, India and her Doctor of Philosophy (PhD) in Pharmacoeconomics and Health Outcomes from Virginia Commonwealth University, Richmond.

During an internship with Avalere Health, a healthcare consulting firm, Batul led a literature review evaluating barriers to optimal use of multiple daily injections and provided clinical and economic research support for an economic model evaluating fecal microbiota transplantation for clostridium difficile infections. She also provided critical research support on a variety of HTA submissions, issue briefs and white papers.

During the course of her graduate program, Batul led several projects ranging from estimating prescription drug use not captured in claims databases to estimating the cost of prescription opioid overdose. She also collaborated with pharmacists at the VCU Health System to study outcomes in a collaborative pharmacist-physician practice model. Through the course of her education and Fellowship, Batul has disseminated her research at several ISPOR, AMCP and other international congresses.

Batul currently supports the US HE&OR Early Development team and works across the Neuroscience and Immunology/Transplant therapeutic areas. She continues to work on projects supporting the HE&OR strategy and tactics for the pipeline products for Multiple Sclerosis, Narcolepsy, Spinal Muscular Atrophy (SMA), Primary Sjogren’s Syndrome (pSS) and Non-Alcoholic Steatohepatitis (NASH).

Post-Doctoral Fellow:
Rahul Garg, PhD

Rahul Garg is a post-doctoral Health Economics and Outcomes Research Fellow with Novartis Pharmaceuticals Corporation.

Rahul received his Doctor of Philosophy (PhD) from the West Virginia University (WVU). Prior to the Fellowship, he had a variety of research experiences and five first-authored manuscripts while he was at WVU. During his experience at WVU, Rahul worked on numerous healthcare claims and survey databases such as NHANES, MCBS, SEER-Medicare, and HUMANA insurance claims. He designed and conducted surveys among women of children under 3 years of age for vaccination. He also designed a survey for Folic acid intake among women of child bearing age. Rahul has extensive experience in working with national databases. He published two manuscripts using MCBS for patient-centered care and propensity to seek care among elderly Medicare beneficiaries. He also analyzed HUMANA insurance database to examine use of rapid acting insulin in elderly diabetes patients for a grant project for Sanofi. His PhD dissertation research utilized SEER-Medicare database to examine the care and utilization among elderly patients with Diffuse Large B-Cell Lymphoma.

As part of the Novartis Fellowship, he is involved in several HE&OR research projects and gaining hands-on experience in the industry. He holds various strategic roles, including project management and leading in-line products. His interests lie in utilizing patient reported outcomes, analyzing retrospective database analyses, economic modeling, HE&OR methodologies, and project management and formulating strategy. He is looking forward to further developing expertise in HE&OR in the pharmaceutical industry.
Previous Fellows

Neetu Agashivala, MS  
Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Kelly Fee Bell, PharmD, MSPhr  
Director, Health Economics & Outcomes Research, US Medical Affairs, AstraZeneca

William Boyko, PharmD  
Clinical Account Executive, Express Scripts

Cat Bui, PharmD  
Director, Health Economics & Outcomes Research, Astellas Pharma US, Inc.

Scott Bull, PharmD  
Director, Clinical Development, Johnson & Johnson Pharmaceutical Research & Development

Belieil Cai, PhD, MA  
Associate Director, Health Economics and Outcomes Research, Novartis Oncology

Jane Chang, MPH  
Director, Outcomes & Evidence, Pfizer

Paul C. Cockrum, PharmD, DPh  
President, HealthKinetics Consulting

QuynhChau Doan, MS, RPh, PhD  
Medical Outcomes Science Liaison, AbbVie

John Fastenau, PhD, MPH, RPh  
Team Leader, Real World Evidence, Janssen Scientific Affairs, LLC

Feride Frech-Tamas, PhD, MPH  
Executive Director, Epidemiology and Outcomes Research, Lexicon Pharmaceuticals

Boris Gorsch, PharmD  
Director, Value Evidence and Outcomes, GlaxoSmithKline

Geneen Graber, PharmD  
President and CEO, DrG's Pharmacy

Bill Grant, PhD  
Associate Professor of Economics, College of Business, James Madison University

Amy Grogg, PharmD  
Senior Vice President, Strategy and Commercialization, AmnealSource Bergen Specialty Group

Kristy Hanson, PharmD, MS  
Scientific Consultant, United BioSource Corporation

Perry Hur, PharmD, MBA  
Associate Director, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation

Tom Karagiannis, PharmD, MS  
Outcomes Research Scientist, Patient-Centered Outcomes Research - Oncology, Genentech, Inc.

Jennifer Kim, PharmD  
Director, Global Price and Reimbursement, AstraZeneca

John Kim, PharmD  
Director, Value Access & Policy (Intercontinental Region), Amgen, Inc.

Yoona Kim, PharmD, PhD  
Head of Clinical Modeling and Analytics, Proteus Digital Health

John Ko, PharmD, MS  
Associate Director, Value & Evidence Strategy, Alnylam

Amy Law, PharmD, MS  
Deputy Director, US Health Economics & Outcomes Research, Bayer HealthCare Pharmaceuticals, Inc.

Jackie Lu, PharmD, MS  
Regional Clinical Account Director, AstraZeneca

Mario Luong, PharmD, MPH  
Innovations Lead, UnitedHealth Group

Jeannie Menz, PharmD  
Associate Director, Medical Information and Communication, Novartis Pharmaceuticals Corporation

Gilbert C. Nigan  
Clinical Manager, Caremark

Lina Nol-Heiring, MBA, RPh  
Dermatology Sales Professional, Valeant Pharmaceuticals

Engels Obe, PhD  
Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Jacqueline B. Palmer, PharmD  
Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Jina Park, PharmD  
Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Hoa T. Pham  
Medical Science Director, ZS Pharma, Inc.

Craig Plauschinen, PharmD, MPH  
Senior Director, Clinical Outcomes Analytics and Research, Magellan Health Services

Karina Raimundo, MS  
Health Economist, Health Economics & Outcomes Research, Genentech, Inc.

Sweetha Rapaia  
Analytics Consultant, Cigna

David Ray, PharmD, MBA, MPH  
HEOR Manager, Ipsen Biopharmaceuticals

Rahul Sasané, PhD, MS, BPharm  
Senior Director, Health Economics & Outcomes Research, Novartis Oncology

Veronica Sendersky, PharmD  
Managing Director/Freelance, Excellent Pharma Consulting

Hemal Shah, PharmD  
Independent Consultant/Principal, Healthcare Quality & Value Strategies, LLC

Engels Obe, PharmD  
Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Anh Singhania, PharmD  
Medical Science Director - Managed Market, HEOR, ZS Pharma Inc.

Liz Stanley Smart, PharmD  
Senior Medical Liaison, Health Economics & Outcomes Research, Boehinger Ingelheim

Bhavini Patel Srivastava, BSBS, MS  
Manager, Health Economics & Outcomes Research, Pharmacyclics

Kangho Suh, PharmD, MS  
PhD student, Pharmaceutical Outcomes Research & Policy, University of Washington

Dusica Tasic  
Manager, Health Economics & Outcomes Research, GE Healthcare

Devi Thaker, PharmD  
Director, PharmacoAnalytics, Express Scripts

Melody Tran, PharmD, MS  
Sr Clinical and Health Economics Specialist, Proteus Digital Health

Yuen Tsang, PharmD, MPH  
Senior Medical Liaison, Managed Markets and Health Economics & Outcomes Research, Actelion Pharmaceuticals

Stefan Varga, PharmD  
Manager, Global Value & Access Strategy, Eisai Inc

Ashok Vegesna, PharmD, MS  
Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Joel Wallace, PharmD, MPH  
Director, Real World Evidence, Novartis Pharmaceuticals Corporation

Anh Singhania, PharmD  
Medical Science Director - Managed Market, HEOR, ZS Pharma Inc.

Liz Stanley Smart, PharmD  
Senior Medical Liaison, Health Economics & Outcomes Research, Boehinger Ingelheim

Bhavini Patel Srivastava, BSBS, MS  
Manager, Health Economics & Outcomes Research, Pharmacyclics

Kangho Suh, PharmD, MS  
PhD student, Pharmaceutical Outcomes Research & Policy, University of Washington

Dusica Tasic  
Manager, Health Economics & Outcomes Research, GE Healthcare

Devi Thaker, PharmD  
Director, PharmacoAnalytics, Express Scripts

Melody Tran, PharmD, MS  
Sr Clinical and Health Economics Specialist, Proteus Digital Health

Yuen Tsang, PharmD, MPH  
Senior Medical Liaison, Managed Markets and Health Economics & Outcomes Research, Actelion Pharmaceuticals

Stefan Varga, PharmD  
Manager, Global Value & Access Strategy, Eisai Inc

Ashok Vegesna, PharmD, MS  
Associate Director, Health Economics & Outcomes Research, Novartis Pharmaceuticals Corporation

Joel Wallace, PharmD, MPH, MBA  
Global Business Strategy Head, Chugai Pharmaceutical Co

Pin Xiang, PharmD  
Manager, Global Health Economics, Amgen

Krista Yokoyama, PharmD  
Sr Manager, Pharmacy Analytics, Blue Shield of California
Health Economics & Outcomes Research Fellowship Application Form

Please type or print

Name:
______________________________________________________________________________________________________

Last First MI

Address:
______________________________________________________________________________________________________

Street City State Zip Code

Phone:
______________________________________________________________________________________________________

Primary Secondary

Email:
_________________________________________________________________

Undergraduate and Graduate Degree(s) (date received or expected):
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________

2-Year Programs (Preferred Degrees: PharmD, PhD, MS)
Applications Due December 10, 2017; Anticipated Start June/July 2018
Please rank your site(s) of interest in order of priority (1 as highest priority):

______ Baylor Scott & White Health/The University of Texas at Austin/Novartis Pharmaceuticals Corporation
______ The University of Maryland/Novartis Pharmaceuticals Corporation
______ Thomas Jefferson University College of Population Health/Novartis Pharmaceuticals Corporation

1-Year Programs (Preferred Degrees: PhD)
Applications accepted on rolling basis

______ Novartis Pharmaceuticals Corporation

Application Materials Required
• Application form
• Curriculum vitae
• Letter of intent (make specific to top choice)
• Three letters of recommendation (must be forwarded directly by the authors of these letters)
• Official academic transcript(s) (must be forwarded directly from the Registrar’s Office)

Please email or send the required application materials by December 10, 2017 to:
Health Economics & Outcomes Research Fellowship
One Health Plaza, Building 125/2416A, East Hanover, NJ 07936
Email: HEOR.fellowship@novartis.com